Recognizing that the fevered finger-pointing and congressional calls for investigations into escalating drug prices won't subside after Tuesday's election, the U.S. biopharma industry is ramping up social media campaigns and lobbying efforts to demonstrate the need for a systemic cure to a broken health care system rather than dusted-off bandages that could make the problem worse.